Symbiotec Pharmalabs shares jump 19% on European protein deal
In short
Symbiotec Pharmalabs shares climbed 19% to a fresh high after the company announced a 10-year deal with a European protein innovator.
The company said the fermentation-based protein is aimed at clean, nutritious alternatives. It also said the deal supports its work in alternative protein, human nutrition and industrial bioproducts.
What the reporting says
Symbiotec Pharmalabs shares surged 19% to a new post-listing high after the company announced a 10-year deal with a European protein innovator. The move came as the company highlighted fermentation-driven protein as a milestone in clean, nutritious alternatives and said it is positioned to serve alternative protein, human nutrition and industrial bioproducts sectors.
Why it matters
Symbiotec Pharmalabs shares moved sharply higher after news of a 10-year agreement with a European protein innovator. The company framed the deal as a step into fermentation-driven protein and said it can serve alternative protein, human nutrition and industrial bioproducts markets.